EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

Abstract

Objectives: To develop the European League Against Rheumatism (EULAR) recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis. Methods: An expert consensus group was formed consisting of rheumatologists, nephrologists and specialists in internal medicine representing five European countries and the USA, a clinical epidemiologist and representatives from regulatory agencies. Using an evidence-based and expert opinion-based approach in accordance with the standardised EULAR operating procedures, the group identified nine topics for a systematic literature search through a modified Delphi technique. On the basis of research questions posed by the group, recommendations were derived for conducting clinical studies and/or clinical trials in systemic vasculitis. Results: Based on the results of the literature research, the expert committee concluded that sufficient evidence to formulate guidelines on conducting clinical trials was available only for anti-neutrophil cytoplasm antibodyassociated vasculitides (AAV). It was therefore decided to focus the recommendations on these diseases. Recommendations for conducting clinical trials in AAV were elaborated and are presented in this summary document. It was decided to consider vasculitis-specific issues rather than general issues of trial methodology. The recommendations deal with the following areas related to clinical studies of vasculitis: definitions of disease, activity states, outcome measures, eligibility criteria, trial design including relevant end points, and biomarkers. A number of aspects of trial methodology were deemed important for future research. Conclusions: On the basis of expert opinion, recommendations for conducting clinical trials in AAV were formulated. Furthermore, the expert committee identified a strong need for well-designed research in non-AAV systemic vasculitides.

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody–associated vasculitis

“…It was not a requirement that ANCA be present at initiation of rituximab. All patients received rituximab as off-label therapy for refractory disease, encompassing those whose disease had failed to remit or had relapsed despite standard immunosuppression, as well as patients in whom standard therapies were contraindicated (22). Patients treated with rituximab as first-line therapy were excluded, as were those with fewer than 6 months of followup after a first rituximab course.…”

“…Complete remission was defined as the absence of disease symptoms and signs with a reduction in the steroid dosage (22). Partial remission was defined as a Ͼ50% reduction in disease activity, as assessed by the Disease Extent Index (DEI) (23).…”

Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's)

“…Disease activity was assessed by the BVAS index (5,15,16). A BVAS score of 0 corresponded to remitted disease.…”

Intravenous Immunoglobulin as an Immunomodulating Agent in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A French Nationwide Study of Ninety‐Two Patients

“…Characteristics at the initiation of IVIG therapy are referred to as the baseline characteristics. Response to therapy was defined according to the recommendations of the European League Against Rheumatism (19). Remission was defined as the absence of signs and symptoms attributable to active disease (i.e., BVAS score of 0), and response was defined as a .50% reduction in disease activity as assessed by the BVAS in the absence of new manifestations.…”